AbbVie Inc. (ABBV) Net Profit Margin: 5.79%
Is AbbVie Inc.’s net profit margin high or low?
AbbVie Inc.'s net profit margin of 5.79% is 53% below its 5-year average of 12.41%, near the low end of its 5-year range (5.79%–20.54%).
As of Wednesday, June 17, 2026. 20.14% below its 12-month average of 7.25%.
ABBV Net Profit Margin Chart
ABBV Average Net Profit Margin Chart
ABBV Current vs Average Net Profit Margin Chart
ABBV Net Profit Margin Metrics
NET PROFIT MARGIN
5.79%
NET PROFIT MARGIN AVG TTM
7.25%
NET PROFIT MARGIN AVG 3Y
10.96%
NET PROFIT MARGIN AVG 5Y
12.41%
NET PROFIT MARGIN AVG 10Y
16.37%
NET PROFIT MARGIN AVG 15Y
17.88%
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-20.14%
CURRENT VS 3Y AVG
-47.17%
CURRENT VS 5Y AVG
-53.34%
CURRENT VS 10Y AVG
-64.63%
CURRENT VS 15Y AVG
-67.61%
CURRENT VS 20Y AVG
N/A
ABBV Competitors' Net Profit Margin
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| AbbVie Inc. (ABBV) | $393.06B | 5.79% | 7.25% | 10.96% | 12.41% |
| UnitedHealth Group Incorporated (UNH)vs › | $370.21B | 2.68% | 3.15% | 4.63% | 5.09% |
| Merck & Co., Inc. (MRK)vs › | $284.45B | 13.62% | 27.40% | 19.98% | 20.62% |
| AstraZeneca PLC (AZN)vs › | $275.88B | 17.19% | 15.23% | 12.72% | 10.53% |
| Johnson & Johnson (JNJ)vs › | $566.13B | 21.83% | 22.15% | 27.00% | 25.39% |
| Novo Nordisk A/S (NVO)vs › | $193.39B | 37.14% | 33.96% | 33.83% | 33.74% |
| Amgen Inc. (AMGN)vs › | $187.59B | 20.95% | 16.61% | 20.49% | 22.20% |
| Thermo Fisher Scientific Inc. (TMO)vs › | $175.64B | 15.18% | 14.95% | 14.84% | 16.47% |
| Gilead Sciences, Inc. (GILD)vs › | $158.06B | 30.99% | 15.29% | 17.07% | 15.27% |
| Abbott Laboratories (ABT)vs › | $157.84B | 13.91% | 23.34% | 19.20% | 17.71% |
Margin Comparison
Operating Margin
27.6%
Net Profit Margin
5.8%
AbbVie Inc. Net Profit Margin Formula & Definition
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
AbbVie Inc. Net Profit Margin FAQ
- What is the net profit margin for AbbVie Inc. (ABBV)?
- The net profit margin for ABBV stock is 5.79%.
- Is AbbVie Inc.'s net profit margin high or low?
- AbbVie Inc.'s net profit margin of 5.79% is 53% below its 5-year average of 12.41%, near the low end of its 5-year range (5.79%–20.54%).
- What is the TTM average net profit margin for AbbVie Inc. (ABBV)?
- The TTM average net profit margin for ABBV stock is 7.25%.
- What is the 3Y average net profit margin for AbbVie Inc. (ABBV)?
- The 3Y average net profit margin for ABBV stock is 10.96%.
- What is the 5Y average net profit margin for AbbVie Inc. (ABBV)?
- The 5Y average net profit margin for ABBV stock is 12.41%.
- What is the 10Y average net profit margin for AbbVie Inc. (ABBV)?
- The 10Y average net profit margin for ABBV stock is 16.37%.
- What is the 15Y average net profit margin for AbbVie Inc. (ABBV)?
- The 15Y average net profit margin for ABBV stock is 17.88%.
AbbVie Inc. Net Profit Margin History
| DATE | NET PROFIT MARGIN |
|---|---|
| 2025-12-31 | 6.91% |
| 2024-12-31 | 7.59% |
| 2023-12-31 | 8.95% |
| 2022-12-31 | 20.39% |
| 2021-12-31 | 20.54% |
| 2020-12-31 | 10.08% |
| 2019-12-31 | 23.69% |
| 2018-12-31 | 17.36% |
| 2017-12-31 | 18.82% |
| 2016-12-31 | 23.22% |
| 2015-12-31 | 22.50% |
| 2014-12-31 | 8.89% |
| 2013-12-31 | 21.97% |
| 2012-12-31 | 28.70% |
| 2011-12-31 | 19.68% |
| 2010-12-31 | 26.72% |
| 2009-12-31 | 32.62% |
Related Metrics
About AbbVie Inc.
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Robert A. Michael